# Precipio, Inc. (PRPO)

> Source: Nexqual · https://nexqual.com/PRPO · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Precipio, Inc. (PRPO), nexqual.com/PRPO" · informational, not investment advice.

**Price:** USD 20.01 (-2.91% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 20.61 · day 20–20.65 · 52w 18.5–33.63 · market cap $35.8M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $27.7M, net income -$1.2M (-4.4% margin), free cash flow $789K (SEC filings).
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $100K; 2 not under a Rule 10b5-1 plan ($100K); 2 by opportunistic insiders (2 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $1K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -2.6% vs S&P 500 +13.4%; 5Y -57.6% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $9.8M | $15.4M | $18.6M | $24.2M | $27.7M |
| Gross profit | $2.4M | $2.5M | $6.0M | $7.6M | $10.7M | — |
| Operating income | -$9.6M | -$12.8M | -$7.6M | -$4.2M | -$1.2M | -$1.5M |
| Net income | -$8.5M | -$12.2M | -$5.9M | -$4.3M | -$363K | -$1.2M |
| EPS (diluted) | -$8.00 | -$10.73 | -$4.51 | -$2.93 | -$0.23 | — |
| Free cash flow | -$7.3M | -$8.0M | -$3.7M | $216K | $359K | $789K |
| Gross margin | 27.0% | 25.6% | 39.0% | 40.7% | 44.2% | — |
| Operating margin | -108.6% | -130.3% | -49.4% | -22.7% | -5.0% | -5.6% |
| Net margin | -96.2% | -124.0% | -38.0% | -23.1% | -1.5% | -4.4% |
| Revenue growth | +19.1% | +11.0% | +57.0% | +20.5% | +30.5% | — |
| Cash + short-term investments | $11.7M | $3.4M | $1.5M | $1.4M | $2.7M | — |
| Total debt | $186K | $404K | $353K | $383K | $83K | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 1.3x · EV/Sales 1.2x · P/FCF 45.4x · P/B 2.4x · FCF yield 2.20% · Earnings yield -3.39% · Net cash $2.8M · EV $33.1M

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-21 | Sandberg Richard A | Director | 900 | $23K | 2.4% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-19…2026-05-20 | Sandberg Richard A | Director | 3,134 | $78K | 7.8% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $1K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-01 | Sabet Ahmed Zaki | Chief Operating Officer | 19 | $1K | 27.93 | Too little history (no open-market trades in 2024) |

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -2.6% | -57.6% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -2.6% | -15.8% |
| Volatility (annualized) | 60.4% | 66.2% |
| Max drawdown | -38.2% (May 2026→Oct 2026) | -90.1% (Oct 2021→Jul 2024) |

## Peers (Diagnostics & Research)
FLGT (Fulgent Genetics, Inc.) USD 20.1 +0.55% · MYGN (Myriad Genetics, Inc.) USD 5.82 +1.04% · CSTL (Castle Biosciences, Inc.) USD 33.08 -0.33% · OPK (Opko Health, Inc.) USD 1.63 +0.00% · FRNM (Freenome, Inc.) USD 12.77 -2.52% · WGS (GeneDx Holdings Corp.) USD 56.15 -16.37%

## More
Full page: https://nexqual.com/PRPO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Service Revenue Net | $6.1M | 87.1% | +22.2% |
| Product | $906,000 | 12.9% | +45.2% |
| Total revenue | $7.0M | 100% | — |

## Customer concentration

Period ended 2026-06-30: 30% of revenue from unnamed direct customers (10-Q, filed 2026-08-14).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter (ends 2024-03-31) | — | — | — | $0 | — |
| Current fiscal year (ends 2023-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |